PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
The most common of these is solitary plasmacytoma of bone (SPB), accounting for 3–5% of all plasma cell malignancies. Prognostic Nomogram for Predicting Overall Survival of Solitary Bone Plasmacytoma
Continue reading“”Solitary plasmacytoma (SP) is an early-stage plasma cell malignancy that is in between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) along the spectrum
Continue reading“…plasma cell proliferation results in a solitary lesion (solitary bone plasmacytoma or extramedullary plasmacytoma…acute cauda equina syndrome (CES) secondary to solitary bone plasmacytoma
Continue reading